In addition, ION363 was administered to a single human ALS patient with a FUS-P525L mutation by repeated intrathecal infusions, which provided the first preliminary evidence that this treatment can lower insoluble levels of wild-type and mutant FUS in the human nervous system [412]. Here, FUS is linked to amyotrophic lateral sclerosis.